Free Trial

Leap Therapeutics (LPTX) Stock Price, News & Analysis

Leap Therapeutics logo
$0.29 -0.01 (-2.30%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$0.29 +0.00 (+0.21%)
As of 08/29/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Leap Therapeutics Stock (NASDAQ:LPTX)

Key Stats

Today's Range
$0.29
$0.30
50-Day Range
$0.24
$0.37
52-Week Range
$0.22
$4.79
Volume
294,954 shs
Average Volume
2.32 million shs
Market Capitalization
$11.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.38
Consensus Rating
Hold

Company Overview

Leap Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

LPTX MarketRank™: 

Leap Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 542nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Leap Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Leap Therapeutics has received no research coverage in the past 90 days.

  • Read more about Leap Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Leap Therapeutics are expected to grow in the coming year, from ($1.84) to ($1.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Leap Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Leap Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Leap Therapeutics has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Leap Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.98% of the float of Leap Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Leap Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Leap Therapeutics has recently decreased by 25.37%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Leap Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Leap Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.98% of the float of Leap Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Leap Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Leap Therapeutics has recently decreased by 25.37%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Leap Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Leap Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Leap Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.50% of the stock of Leap Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 30.46% of the stock of Leap Therapeutics is held by institutions.

  • Read more about Leap Therapeutics' insider trading history.
Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LPTX Stock News Headlines

Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
Leap Therapeutics, Inc. (LPTX) - Yahoo Finance
See More Headlines

LPTX Stock Analysis - Frequently Asked Questions

Leap Therapeutics' stock was trading at $2.88 at the start of the year. Since then, LPTX shares have decreased by 90.0% and is now trading at $0.2884.

Leap Therapeutics, Inc. (NASDAQ:LPTX) released its earnings results on Thursday, August, 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.11.

Leap Therapeutics shares reverse split on the morning of Wednesday, June 21st 2023.The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Leap Therapeutics' top institutional shareholders include Simplify Asset Management Inc. (2.07%), Key Client Fiduciary Advisors LLC (0.83%), Group One Trading LLC and Simplex Trading LLC.
View institutional ownership trends
.

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Leap Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Vaxart (VXRT) and OPKO Health (OPK).

Company Calendar

Last Earnings
8/14/2025
Today
8/30/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LPTX
CIK
1509745
Fax
N/A
Employees
40
Year Founded
2011

Price Target and Rating

High Price Target
$5.50
Low Price Target
$1.25
Potential Upside/Downside
+1,070.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$67.56 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-237.65%
Return on Assets
-155.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.34
Quick Ratio
1.34

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.14 per share
Price / Book
2.06

Miscellaneous

Outstanding Shares
41,440,000
Free Float
38,332,000
Market Cap
$11.95 million
Optionable
Optionable
Beta
-0.27

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:LPTX) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners